Latest Cleveland Biolabs (CBLI) Headlines
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
Marketwire - Tue Mar 11, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31, 2013.
Cleveland BioLabs to Host Fourth Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:06PM CDT
BUFFALO, NY / ACCESSWIRE / March 10, 2014 / Cleveland BioLabs (CBLI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Tuesday, March 11, 2014 at 10:00 AM Eastern Time.
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Feb 27, 12:54PM CST
These under-$10 stocks look ready to trade higher from current levels.
Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
Marketwire - Thu Feb 27, 7:03AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on March 11, 2014, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013, and will host a conference call at 10:00 a.m. ET.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hot Stock: Cleveland Biolabs, Shares Drop 5.4% (CBLI)
Comtex SmarTrend(R) - Thu Feb 13, 11:41AM CST
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 5.4% to $0.70 on 1.2x average daily volume. Cleveland Biolabs has traded 728,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.1%) and underperformed the S&P 500 (-5.8% to the S&P's 0.2%) during today's trading.
Dame Jonathan Pledges to Work With UN Board On Water, Sanitation
All Africa Global Media - Thu Feb 13, 6:25AM CST
First Lady, Dame Patience Jonathan, has promised to work with the UN Advisory Board on Water and Sanitation to ensure better environment in Africa.
Hepatic (Liver) Metastasis - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9wq5t/hepatic_liver) has announced the addition of the "Hepatic (Liver) Metastasis - Pipeline Review, H2 2013" report to their offering. 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis. Scope - A snapshot of the global therapeutic scenario for Hepatic (Liver) Metastasis. - A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hepatic (Liver) Metastasis Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles icosapent - Drug Profile Product Description Mechanism of Action R&D Progress FANG Vaccine - Drug Profile Product Description Mechanism of Action R&D Progress 177Lu-DOTA-TATE - Drug Profile Product Description Mechanism of Action R&D Progress pasireotide - Drug Profile Product Description Mechanism of Action R&D Progress entolimod - Drug Profile Product Description Mechanism of Action R&D Progress Curcumin C3-Complex [fluorouracil] [oxaliplatin] [leucovorin calcium] - Drug Profile Product Description Mechanism of Action R&D Progress mepacrine - Drug Profile Product Description Mechanism of Action R&D Progress disulfiram [copper gluconate] - Drug Profile Product Description Mechanism of Action R&D Progress Salmonella typhimurium - Drug Profile Product Description Mechanism of Action R&D Progress Anti-CEA Designer T Cells - Drug Profile Product Description Mechanism of Action R&D Progress Antibody Against FERM Domain-Containing Protein 4A - Drug Profile Product Description Mechanism of Action R&D Progress Hepatic (Liver) Metastasis - Recent Pipeline Updates Hepatic (Liver) Metastasis - Dormant Projects Hepatic (Liver) Metastasis - Product Development Milestones Featured News & Press Releases Companies Mentioned Novartis AG Cleveland BioLabs, Inc. CytRx Corporation S.L.A. Pharma AG Incuron, LLC Gradalis Inc. TARGETOME For more information visit http://www.researchandmarkets.com/research/v9...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the 2014 BIO CEO & Investor Conference, February 10-11, in New York, NY.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cleveland BioLabs, Inc. - CBLI
PR Newswire - Thu Jan 30, 4:13PM CST
Pomerantz LLP is investigating claims on behalf of investors of Cleveland BioLabs, Inc. ("CBLI" or the "Company") (NasdaqGS: CBLI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 1-888-476-6529, ext. 237.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cleveland BioLabs, Inc.
PR Newswire - Wed Jan 29, 3:05PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NasdaqCM: CBLI). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
Zhone Technologies Earnings Steady Despite Missing Analysts Estimates: Zhone Technologies, Inc. (NASDAQ: ZHNE), Cleveland BioLabs Inc. (NASDAQ:CBLI), FreeSeas Inc. (NASDAQ: FREE)
ACCESSWIRE - Tue Jan 28, 7:16AM CST
In the world of penny stocks, companies that produce consistent earnings stand out. One such company is Zhone Technologies, Inc. (NASDAQ: ZHNE).
Glancy Binkow & Goldberg LLP Announces Investigation of Cleveland BioLabs, Inc.
Business Wire - Fri Jan 24, 8:32PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NASDAQ: CBLI) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Cleveland BioLabs concerning the Company's business and financial prospects.
Investor Alert: Cleveland BioLabs, Inc. Investigation Announced by Holzer & Holzer, LLC
Business Wire - Fri Jan 24, 9:57AM CST
Holzer & Holzer, LLC is investigating whether Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NASDAQ: CBLI) and/or certain of its officers complied with the federal securities laws in connection with the Company's public securities offering on January 14, 2014 (the "Offering"). Specifically, the investigation focuses on statements contained in (and incorporated into) the Registration Statement issued in connection with the Offering regarding funding from the Biomedical Advanced Research Development Authority. On January 23, 2014, just days after the Offering, Cleveland BioLabs announced that BARDA "terminated negotiations related to the company's proposal for further development of Entolimod as a medical radiation countermeasure." The price of CBLI shares fell dramatically on the news.
Downgrade Alert for Cleveland Biolabs (CBLI)
Comtex SmarTrend(R) - Fri Jan 24, 7:03AM CST
Cleveland Biolabs (NASDAQ:CBLI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $0.75 on volume of 5.2 million shares, above average daily volume of 257,000. Cleveland Biolabs has overhead space with shares priced $0.75, or 81.3% below the average consensus analyst price target of $4.00. The stock should find initial resistance at its 50-day moving average (MA) of $1.24 and further resistance at its 200-day MA of $1.54.
Cleveland Biolabs Down 33.6%, Shares Slide into the Red (CBLI)
Comtex SmarTrend(R) - Thu Jan 23, 10:11AM CST
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 33.6% to $0.75 on 12.5x average daily volume. Thus far today, Cleveland Biolabs has traded 3.2 million shares, vs. average volume of 260,000 shares per day. The stock has underperformed the Dow (-33.6% to the Dow's -1.1%) and underperformed the S&P 500 (-33.6% to the S&P's -1.0%) during today's trading.
Cleveland BioLabs Provides Update on Barda Development Proposal
GlobeNewswire - Thu Jan 23, 6:00AM CST
Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Biomedical Advanced Research and Development Authority ("BARDA") has terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure, noting that all such negotiations are subject to the availability of funds.
Cleveland BioLabs Inc enters into USD7m at-the-market registered direct offering
M2 - Wed Jan 15, 4:23AM CST
Biotechnology company Cleveland BioLabs Inc (NasdaqCM:CBLI) stated on Tuesday that it plans to sell USD7m of its common stock in an at-the-market registered direct offering.
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
Marketwire - Tue Mar 11, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31, 2013.
Cleveland BioLabs to Host Fourth Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:06PM CDT
BUFFALO, NY / ACCESSWIRE / March 10, 2014 / Cleveland BioLabs (CBLI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Tuesday, March 11, 2014 at 10:00 AM Eastern Time.
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Feb 27, 12:54PM CST
These under-$10 stocks look ready to trade higher from current levels.
Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
Marketwire - Thu Feb 27, 7:03AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on March 11, 2014, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013, and will host a conference call at 10:00 a.m. ET.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hot Stock: Cleveland Biolabs, Shares Drop 5.4% (CBLI)
Comtex SmarTrend(R) - Thu Feb 13, 11:41AM CST
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 5.4% to $0.70 on 1.2x average daily volume. Cleveland Biolabs has traded 728,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.1%) and underperformed the S&P 500 (-5.8% to the S&P's 0.2%) during today's trading.
Dame Jonathan Pledges to Work With UN Board On Water, Sanitation
All Africa Global Media - Thu Feb 13, 6:25AM CST
First Lady, Dame Patience Jonathan, has promised to work with the UN Advisory Board on Water and Sanitation to ensure better environment in Africa.
Hepatic (Liver) Metastasis - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9wq5t/hepatic_liver) has announced the addition of the "Hepatic (Liver) Metastasis - Pipeline Review, H2 2013" report to their offering. 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis. Scope - A snapshot of the global therapeutic scenario for Hepatic (Liver) Metastasis. - A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hepatic (Liver) Metastasis Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles icosapent - Drug Profile Product Description Mechanism of Action R&D Progress FANG Vaccine - Drug Profile Product Description Mechanism of Action R&D Progress 177Lu-DOTA-TATE - Drug Profile Product Description Mechanism of Action R&D Progress pasireotide - Drug Profile Product Description Mechanism of Action R&D Progress entolimod - Drug Profile Product Description Mechanism of Action R&D Progress Curcumin C3-Complex [fluorouracil] [oxaliplatin] [leucovorin calcium] - Drug Profile Product Description Mechanism of Action R&D Progress mepacrine - Drug Profile Product Description Mechanism of Action R&D Progress disulfiram [copper gluconate] - Drug Profile Product Description Mechanism of Action R&D Progress Salmonella typhimurium - Drug Profile Product Description Mechanism of Action R&D Progress Anti-CEA Designer T Cells - Drug Profile Product Description Mechanism of Action R&D Progress Antibody Against FERM Domain-Containing Protein 4A - Drug Profile Product Description Mechanism of Action R&D Progress Hepatic (Liver) Metastasis - Recent Pipeline Updates Hepatic (Liver) Metastasis - Dormant Projects Hepatic (Liver) Metastasis - Product Development Milestones Featured News & Press Releases Companies Mentioned Novartis AG Cleveland BioLabs, Inc. CytRx Corporation S.L.A. Pharma AG Incuron, LLC Gradalis Inc. TARGETOME For more information visit http://www.researchandmarkets.com/research/v9...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
5 Biotech Stocks to Trade in February
at The Street - Mon Feb 10, 1:15PM CST
These biotech stocks scheduled to present at the BIO CEO conference could be poised for sharp spikes higher.
Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the 2014 BIO CEO & Investor Conference, February 10-11, in New York, NY.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cleveland BioLabs, Inc. - CBLI
PR Newswire - Thu Jan 30, 4:13PM CST
Pomerantz LLP is investigating claims on behalf of investors of Cleveland BioLabs, Inc. ("CBLI" or the "Company") (NasdaqGS: CBLI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 1-888-476-6529, ext. 237.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cleveland BioLabs, Inc.
PR Newswire - Wed Jan 29, 3:05PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NasdaqCM: CBLI). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
Zhone Technologies Earnings Steady Despite Missing Analysts Estimates: Zhone Technologies, Inc. (NASDAQ: ZHNE), Cleveland BioLabs Inc. (NASDAQ:CBLI), FreeSeas Inc. (NASDAQ: FREE)
ACCESSWIRE - Tue Jan 28, 7:16AM CST
In the world of penny stocks, companies that produce consistent earnings stand out. One such company is Zhone Technologies, Inc. (NASDAQ: ZHNE).
Glancy Binkow & Goldberg LLP Announces Investigation of Cleveland BioLabs, Inc.
Business Wire - Fri Jan 24, 8:32PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NASDAQ: CBLI) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Cleveland BioLabs concerning the Company's business and financial prospects.
Investor Alert: Cleveland BioLabs, Inc. Investigation Announced by Holzer & Holzer, LLC
Business Wire - Fri Jan 24, 9:57AM CST
Holzer & Holzer, LLC is investigating whether Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NASDAQ: CBLI) and/or certain of its officers complied with the federal securities laws in connection with the Company's public securities offering on January 14, 2014 (the "Offering"). Specifically, the investigation focuses on statements contained in (and incorporated into) the Registration Statement issued in connection with the Offering regarding funding from the Biomedical Advanced Research Development Authority. On January 23, 2014, just days after the Offering, Cleveland BioLabs announced that BARDA "terminated negotiations related to the company's proposal for further development of Entolimod as a medical radiation countermeasure." The price of CBLI shares fell dramatically on the news.
Downgrade Alert for Cleveland Biolabs (CBLI)
Comtex SmarTrend(R) - Fri Jan 24, 7:03AM CST
Cleveland Biolabs (NASDAQ:CBLI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $0.75 on volume of 5.2 million shares, above average daily volume of 257,000. Cleveland Biolabs has overhead space with shares priced $0.75, or 81.3% below the average consensus analyst price target of $4.00. The stock should find initial resistance at its 50-day moving average (MA) of $1.24 and further resistance at its 200-day MA of $1.54.
Cleveland Biolabs Down 33.6%, Shares Slide into the Red (CBLI)
Comtex SmarTrend(R) - Thu Jan 23, 10:11AM CST
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 33.6% to $0.75 on 12.5x average daily volume. Thus far today, Cleveland Biolabs has traded 3.2 million shares, vs. average volume of 260,000 shares per day. The stock has underperformed the Dow (-33.6% to the Dow's -1.1%) and underperformed the S&P 500 (-33.6% to the S&P's -1.0%) during today's trading.
Cleveland BioLabs Provides Update on Barda Development Proposal
GlobeNewswire - Thu Jan 23, 6:00AM CST
Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Biomedical Advanced Research and Development Authority ("BARDA") has terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure, noting that all such negotiations are subject to the availability of funds.
Cleveland BioLabs Inc enters into USD7m at-the-market registered direct offering
M2 - Wed Jan 15, 4:23AM CST
Biotechnology company Cleveland BioLabs Inc (NasdaqCM:CBLI) stated on Tuesday that it plans to sell USD7m of its common stock in an at-the-market registered direct offering.
